Press Releases June 1, 2026 04:00 PM

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure files delayed Form 10-Q, regains Nasdaq compliance amid strategic review

By Derek Hwang XCUR

Exicure, Inc. disclosed receipt of a Nasdaq notice due to delayed filing of its Q1 2026 Form 10-Q, which was subsequently filed, restoring compliance. The company is in a transition phase following restructuring, suspension of clinical activities, and is currently exploring strategic alternatives to maximize shareholder value while advancing a clinical-stage program targeting hematologic diseases.

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
XCUR

Key Points

  • Received Nasdaq notification for delayed Q1 2026 financial filing, now resolved by filing the Form 10-Q.
  • Following restructuring, Exicure suspended clinical activities and acquired a clinical-stage biotech focused on hematologic disease therapeutics.
  • Company is evaluating strategic alternatives to maximize shareholder value, with a lead program in stem cell mobilization for multiple myeloma and sickle cell disease.
  • Sectors impacted include biotechnology, healthcare, pharmaceuticals, and capital markets due to regulatory and strategic developments.

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) --  Exicure, Inc. (Nasdaq: XCUR, the “Company”) announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 28, 2026 indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2026.

The delay was primarily due to additional time required following changes in the Company’s financial reporting personnel and related filing procedures.

The Company filed its Quarterly Report on Form 10-Q for the three months ended March 31, 2026 with the Securities and Exchange Commission on May 29, 2026 and believes that it has regained compliance with Nasdaq Listing Rule 5250(c)(1).

About Exicure, Inc.

Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value. In January 2025, it acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases. The Company’s lead program in development is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. For more information, visit www.exicuretx.com.

Cautionary Note Regarding Forward Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements related to the Company’s review and analysis in connection with the Form 10-Q and the Company’s expectations with respect to its financial results for the three months ended March 31, 2026 and the definitive filing date of the Form 10-Q. Forward-looking statements are based on management’s current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. For a discussion of risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 25, 2026, as updated by the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information or to publicly announce the results of any revisions to any of such statements to reflect future events or developments, except as required by law.

Media Contact:

Exicure, Inc.

[email protected]


Risks

  • Delays in financial reporting may impact investor confidence and regulatory standing.
  • Ongoing suspension of clinical and development activities introduces uncertainty regarding future product pipeline progress.
  • Strategic alternatives under review could lead to significant changes in company direction, affecting shareholder value and operations.

More from Press Releases

Verizon declares quarterly dividend on June 4, 2026 Jun 4, 2026 AmperCap Acquisition Company Completes its $125,000,000 Initial Public Offering Jun 4, 2026 Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026 SOLV Energy Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares of Class A Common Stock Jun 4, 2026 NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option Jun 4, 2026